Xiangbin Tan^*1, Zefei Liao^†1, Shuangyou Zou^*, Liangyun Ma^†, Aimin Wang^*

Oncology Research, Vol.28, No.1, pp. 3-11, 2020, DOI:10.3727/096504019X15509383469698

Abstract Vasohibin2 (VASH2), a proangiogenic factor, has been demonstrated to play an oncogenic role in some common human cancers. However, the detailed function of VASH2 in non-small cell lung cancer (NSCLC) has not previously been studied. In this study, we found that VASH2 was significantly upregulated in NSCLC tissues and cell lines, and its increased expression was associated with NSCLC progression and poor prognosis of patients. Knockdown of VASH2 markedly inhibited cell proliferation and P-glycoprotein expression in NSCLC cells. Overexpression of VASH2 enhanced cell proliferation, P-glycoprotein expression, as well as doxorubicin resistance in NSCLC cells. Moreover, the expression levels of VASH2… More >

Yudie Yang^*1, Xia Zhang^†1, Yajie Gao^*, Yan Dong^*, Di Wang^*, Yanping Huang^*, Tianhao Qu^*, Buqun Fan^*, Qizheng Li^*, Chunxia Zhang^*, Xiaonan Cui^*, Bin Zhang^*

Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719

Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is induced by tyrosine kinase inhibitor-targeted… More >

Hangxing Wang^1,#, Jingyun Fang^1,#, Yujiao Wang^2,#, Shuo Li², Zirui Wang², Wei He², Nan Wang¹, Shuang Luo¹, Huimei Zou^3,*, Fan Zhang^4,5,*

Oncologie, Vol.24, No.1, pp. 65-83, 2022, DOI:10.32604/oncologie.2022.021863

Abstract Lung cancer is the most common malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) accounts for the vast majority of cases. At present, its main treatment methods are still traditional surgery, radiotherapy and chemotherapy, with disadvantages such as a high recurrence rate and limited effectiveness. Therefore, a new, better treatment method is urgently needed. Gene editing technology, as a new genetic engineering approach, has shown great potential in gene research, gene therapy and genetic improvement. It has also emerged as a promising treatment for lung cancer. This paper reviews the current… More >

Sridha Ganesh¹, Rui Wang¹, Honglei Chen^1,2

Oncologie, Vol.23, No.3, pp. 335-350, 2021, DOI:10.32604/oncologie.2021.018610

Abstract Non-small cell lung cancer (NSCLC) constitutes about 84% of lung cancer. Hence, increased efforts have been fueled into immunotherapy of NSCLC with immune checkpoint inhibitors (ICIs). ICIs have recently taken off as promising immune-therapeutic methods that have slowed down the progress of NSCLC and equipped patients with survival advantages. However, the long-term respondents tally is less than 20% of the population. This low response rate warrants the need for dynamic biomarkers which will provide insight into the possible response of patients to ICIs. Biomarkers are biological molecules that predict the pathologic state of patients and the potential response they will… More >

Chunya Hu, Yu He^*

Oncologie, Vol.23, No.2, pp. 241-250, 2021, DOI:10.32604/Oncologie.2021.015828

Abstract Objective: The aim of the present study was to investigate the anti-tumor effects of formononetin on human nonsmall cell lung cancer (NSCLC) and its potential molecular mechanism. Methods: A549 cells were treated with different concentrations of formononetin, then detected the cell proliferation, apoptosis and the expression of HIPK2 respectively by MTT assay, flow cytometry analysis and RT-qPCR. Then the interaction between miR- 27a-3p and its target gene HIPK2 was verified through luciferase reporter assay. The expression of miR-27a- 3p, HIPK2, and p53 was detected after being treated with different formononetin concentrations by RT-qPCR and western blot. Results: The results showed… More >

WEIGAO ZHONG^1,*, AIQIN CHEN², XIAOHONG TANG¹, YI LIU¹

BIOCELL, Vol.45, No.4, pp. 901-910, 2021, DOI:10.32604/biocell.2021.08672

Abstract Earlier studies indicated that circular RNAs (circRNAs) were found in various cancer cells, and circFOXM1 was reported to act as an oncogene in non-small cell lung cancer (NSCLC). However, the function of circFOXM1 in NSCLC remains unclear. The expression levels of genes were measured using quantitative real-time polymerase chain reactions (qRT-PCR). Cell proliferation and apoptosis were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (MTT) and flow cytometry assay. The relative protein expression was assessed by western blot. Moreover, transwell assays were employed to examine cell migration and invasion. The targeted relationship was confirmed by dual-luciferase reporter assay. The expression of circFOXM1 was… More >

DAN ZHANG¹, HAIJING LIU¹, ZHENNAN YI², YUANYUAN LU³, YANYAN CHEN⁴, WEIQIANG SU², HUIBING LIN², ZHIHUI ZHANG^5,*, WEI LEI^6,*

BIOCELL, Vol.45, No.3, pp. 617-625, 2021, DOI:10.32604/biocell.2021.012504

Abstract Chemotherapy drug resistance is the main cause leading to the relapse and metastasis of non-small cell lung cancer (NSCLC) patients. Our study aimed to investigate the mechanism of pemetrexed resistance in NSCLC. Firstly, the pemetrexed (PEM)-resistant PC-9 and A549 lung adenocarcinoma cell lines (PC-9/PEM and A549/PEM) were established. The expression of thymidylate synthase (TS) in PC-9/PEM, A549/PEM, A549, and PC-9 cells were analyzed by qRT-PCR and western blot. Then, cell viability, colony formation, migration, and invasion were performed on PEM-resistant cells transfected with TS siRNA. The role of EGFR in PEM resistance of PEM-resistant cells was investigated using EGFR siRNA.… More >

JUNQI GUO^1,2,#, YUN YANG^1,2,#, WEI ZHAO^1,2, ZHONGHAI YAN³, XIA YANG⁴, YUNFEI YAN^1,2, RUIMIN HAO^1,2, JINXIA HU^1,2,*, FEI JIAO^1,2,*

BIOCELL, Vol.45, No.3, pp. 627-638, 2021, DOI:10.32604/biocell.2021.013496

Abstract Increasing evidence indicates that aberrant expressions of some microRNAs are associated with cancer progression. However, the roles and biological mechanisms of miRNA-16-5p in human non-small cell lung cancer (NSCLC) are not to be well studied. Here, we validated that the expression of miR-16-5p was decreased significantly in NSCLC samples and cell lines. The correlation between the clinicopathological features of NSCLC and the miR-16- 5p expression showed that the expression of miR-16-5p in non-small cell lung cancer was linked with the advanced TNM stage, positive lymph node metastasis, with short overall survival (OS). Also, a negative correlation between miR-16-5p and Fermitin… More >

JI ZHU^#, XIYING BO^#, GENGXI JIANG, SHIHUA YAO, TIEJUN ZHAO^*, LING CHEN^*

BIOCELL, Vol.45, No.3, pp. 639-647, 2021, DOI:10.32604/biocell.2021.012847

Abstract Non-small cell lung cancer (NSCLC) cells intake and consume glucose at high efficiency by aerobic glycolysis to maintain robust cell growth and resist cell death. MicroRNAs (miRNAs) have been known to play pivotal roles in NSCLC development partly through mediating glycolysis. However, only a few miRNAs have been experimentally confirmed as critical regulators of glycolysis in NSCLC. TCGA datasets were analyzed to screen for differentially expressed miRNAs between NSCLC and normal tissues. The function of miR-1294-5p was determined in NSCLC cells by cell proliferation, glucose uptake, lactate release, and Extracellular Acidification Rate (ECAR) assays. The target of miR- 1294-5p was… More >

Nan Geng¹, Wenxia Hu¹, Zhikun Liu², Jingwei Su², Wenyu Sun³, Shaonan Xie⁴, Cuimin Ding^1,*

Oncologie, Vol.22, No.4, pp. 245-254, 2020, DOI:10.32604/oncologie.2020.014125

Abstract Objective: This study was set out to inquire into the expression and clinical significance of lncRNA activated by transforming growth factor β (LncRNA-ATB) and in cancer tissues of patients with non-small cell lung cancer (NSCLC). Methods: LncRNA-ATB in cancer tissues and adjacent tissues of 89 NSCLC patients was detected by quantitative real-time polymerase chain reaction (qRT-PCR), and its clinical diagnostic value in NSCLC was determined by receiver operating characteristic (ROC) curves. Based on the median expression of LncRNAATB in NSCLC tissues, 89 patients were allocated into high- and low-expression groups. The 3-year survival rate was calculated using Kaplan-Meier method and… More >